{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["25(1)"],"submitter":["Puranik AD"],"funding":["Tata Memorial Hospital - TMC"],"pubmed_abstract":["<h4>Background</h4>Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE is the standard of care for well-differentiated metastatic or locally advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, tumor heterogeneity, particularly in FDG-avid tumors, can limit treatment effectiveness. The PReCedeNT trial aims to evaluate the efficacy of combining PRRT with capecitabine and temozolomide (CAPE-TEM) chemotherapy compared to PRRT alone in patients with FDG-avid, well-differentiated GEP-NETs.<h4>Methods</h4>This single-center, randomized, open-label, phase III trial will enroll patients with FDG-avid, well-differentiated GEP-NETs. Participants will be randomized in a 1:1 ratio to receive either PRRT alone or PRRT plus CAPE-TEM chemotherapy. The primary end"],"journal":["BMC cancer"],"pagination":["1659"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12560366"],"repository":["biostudies-literature"],"pubmed_title":["PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)."],"pmcid":["PMC12560366"],"pubmed_authors":["Rangarajan V","Bhandare MS","Parghane RV","Shah S","Dev ID","Bhargava P","Venkatachalam M","Chaudhari VA","Puranik AD","Agrawal A","Goel M","Patkar S","Ghosh S","Choudhury S","Ramaswamy A","Basu S","Yadav S","Bal MM","Purandare NC","Ostwal V","Shrikhande SV"],"additional_accession":[]},"is_claimable":false,"name":"PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs).","description":"<h4>Background</h4>Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE is the standard of care for well-differentiated metastatic or locally advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, tumor heterogeneity, particularly in FDG-avid tumors, can limit treatment effectiveness. The PReCedeNT trial aims to evaluate the efficacy of combining PRRT with capecitabine and temozolomide (CAPE-TEM) chemotherapy compared to PRRT alone in patients with FDG-avid, well-differentiated GEP-NETs.<h4>Methods</h4>This single-center, randomized, open-label, phase III trial will enroll patients with FDG-avid, well-differentiated GEP-NETs. Participants will be randomized in a 1:1 ratio to receive either PRRT alone or PRRT plus CAPE-TEM chemotherapy. The primary end","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-05T09:24:24.743Z","creation":"2026-05-15T03:13:06.457Z"},"accession":"S-EPMC12560366","cross_references":{"pubmed":["41152774"],"doi":["10.1186/s12885-025-15111-x"]}}